HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy

A genetic model for colorectal tumorigenesis

Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · see citing works

Genetic Alterations during Colorectal-Tumor Development

Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704 · see citing works

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · see citing works

The consensus molecular subtypes of colorectal cancer

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Ionov, Y., Peinado, M. A., Malkhosyan, S. R., Shibata, D. K., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,707 · see citing works

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J. P., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990 · see citing works

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · see citing works

Estimates of the worldwide mortality from 25 cancers in 1990

Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1 · Cited by 1,529 · see citing works

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · see citing works

Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,173 · see citing works

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. M. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,038 · see citing works

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · see citing works

The Chromosomal Instability Pathway in Colon Cancer

Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 941 · see citing works

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

Garrido, F., Ruiz‐Cabello, F., Cabrera, T., Pérez‐Villar, J. J., López‐Botet, M., Duggan-Keen, M. F., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 768 · see citing works

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722 · see citing works

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · see citing works

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · see citing works

Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy

Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590 · see citing works

The urgent need to recover MHC class I in cancers for effective immunotherapy

Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585 · see citing works

Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

Garnett‐Benson, C., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557 · see citing works

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535 · see citing works

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 496 · see citing works

Natural history of HLA expression during tumour development

Garrido, F., Cabrera, T., Concha, Á., Glew, S., Ruiz‐Cabello, F., & Stern, P. L. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90264-l · Cited by 448 · see citing works

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446 · see citing works

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428 · see citing works

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

Andersen, R. S., Donia, M., Ellebæk, E., Borch, T. H., Kongsted, P., Iversen, T. Z., Hölmich, L. R., Hendel, H. W., Met, Ö., Andersen, M. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1879 · Cited by 318 · see citing works

“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy

Garrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276 · see citing works

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602069113 · Cited by 276 · see citing works

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275 · see citing works

HLA class I antigen abnormalities and immune escape by malignant cells

Seliger, B., Cabrera, T., Garrido, F., & Ferrone, S. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0404 · Cited by 272 · see citing works

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis

Watson, N. F., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21303 · Cited by 254 · see citing works

c‐myc down‐regulates class I HLA expression in human melanomas.

Versteeg, R., Noordermeer, I., Krüse-Wolters, M., Ruiter, D. J., & Schrier, P. I. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02909.x · Cited by 253 · see citing works

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 252 · see citing works

Genomic and immune profiling of pre-invasive lung adenocarcinoma

Chen, H., Carrot‐Zhang, J., Zhao, Y., Hu, H., Freeman, S. S., Yu, S. J., Ha, G., Taylor, A. M., Berger, A. C., Westlake, L. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13460-3 · Cited by 246 · see citing works

The Immune Biology of Microsatellite-Unstable Cancer

Kloor, M., & Doeberitz, M. V. K. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 242 · see citing works

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment

Serrano, A., Tanzarella, S., Lionello, I., Méndez, R., Traversari, C., Ruiz‐Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239 · see citing works

Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis

Menon, A. G., Rhijn, C. M. J., Morreau, H., Putter, H., Tollenaar, R. A. �. �., van de Velde, C. J. �., Fleuren, G. J., & Kuppen, P. J. K. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700055 · Cited by 216 · see citing works

Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling

Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211 · see citing works

BREAST-FED BABIES WHO FAIL TO THRIVE

Stanway, P., & Whichelow, M. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91340-0 · Cited by 201 · see citing works

Cytokine therapy reverses NK cell anergy in MHC-deficient tumors

Ardolino, M., Azimi, C. S., Iannello, A., Trevino, T. N., Horan, L. H., Zhang, L., Deng, W., Ring, A. M., Fischer, S., García, K. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74337 · Cited by 194 · see citing works

Testing guidelines for hereditary non-polyposis colorectal cancer

Umar, A., Risinger, J. I., Hawk, E. T., et al. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1278 · Cited by 184 · see citing works

Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype.

Geiser, A. G., Letterio, J. J., Kulkarni, A. B., Karlsson, S., Roberts, A. B., & Sporn, M. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9944 · Cited by 179 · see citing works

Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal Cancers

Kloor, M., Becker, C., Benner, A., Woerner, S. M., Gebert, J. F., Ferrone, S., & Doeberitz, M. V. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0044 · Cited by 178 · see citing works

High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

Cabrera, T., Collado, A., Fernandez, M. A., Ferron, A., Sancho, J., Ruiz‐Cabello, F., & Garrido, F. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb02274.x · Cited by 175 · see citing works

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer

Simpson, J. A. D., Al‐Attar, A., Watson, N. F., Scholefield, J. H., Ilyas, M., & Durrant, L. G. (2010) · Gut · doi:10.1136/gut.2009.194472 · Cited by 167 · see citing works

Cancer immune escape: MHC expression in primary tumours versus metastases

Garrido, F., & Aptsiauri, N. (2019) · Immunology · doi:10.1111/imm.13114 · Cited by 166 · see citing works

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β 2 ‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

Cabrera, C. M., Jiménez, P., Cabrera, T., Esparza, C., Ruiz‐Cabello, F., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00020.x · Cited by 164 · see citing works

IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours

Seo, H., Jeon, I., Kim, B., Park, M. H., Bae, E., Song, B., Koh, C., Shin, K., Kim, I., Choi, K.-Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15776 · Cited by 164 · see citing works

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

van Hall, T., Wolpert, E. Z., van Veelen, P. A., Laban, S., van der Veer, M., Roseboom, M., Bres-Vloemans, S. A., Grufman, P., de Ru, A., Meiring, H. D., et al. (2006) · Nature Medicine · doi:10.1038/nm1381 · Cited by 160 · see citing works

Rejection versus escape: the tumor MHC dilemma

Garrido, F., Ruiz‐Cabello, F., & Aptsiauri, N. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1947-x · Cited by 157 · see citing works

Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial

Zhang, S., Kohli, K., Black, G., Lu, Y., Spadinger, S. M., He, Q., Pillarisetty, V. G., Cranmer, L. D., Tine, B. A. V., Yee, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0940 · Cited by 155 · see citing works

MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

Angell, T. E., Lechner, M. G., Jang, J. K., LoPresti, J. S., & Epstein, A. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0879 · Cited by 153 · see citing works

Mutations of the β2‐microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

Benitez, R., Godelaine, D., López‐Nevot, M. Á., Brasseur, F., Jimenez, P., Marchand, M.-C., Oliva, M. R., van Baren, N., Cabrera, T., Andry, G., et al. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb03082.x · Cited by 149 · see citing works

Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma

Campo, A. B., Kyte, J. A., Carretero, J., Zinchencko, S., Méndez, R., González‐Aseguinolaza, G., Ruiz‐Cabello, F., Aamdal, S., Gaudernack, G., Garrido, F., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28338 · Cited by 147 · see citing works

Immune evasion of microsatellite unstable colorectal cancers

Kloor, M., Michel, S., & Doeberitz, M. V. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 138 · see citing works

Loss of HLA‐A,B,C and de novo expression of HLA‐D in colorectal cancer

Momburg, F., Degener, T., Bacchus, E., Moldenhauer, G., Hämmerling, G. J., & Möller, P. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910370203 · Cited by 136 · see citing works

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma

Atkins, D., Breuckmann, A., Schmahl, G. E., Binner, P., Ferrone, S., Krummenauer, F., Störkel, S., & Seliger, B. (2003) · International Journal of Cancer · doi:10.1002/ijc.11681 · Cited by 135 · see citing works

Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma

Kalbasi, A. K., Tariveranmoshabad, M., Hakimi, K. N., Kremer, S. V., Campbell, K. M., Funes, J. M., Vega-Crespo, A., Parisi, G., Champhekar, A. S., Nguyen, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0152 · Cited by 133 · see citing works

Selection for β2-microglobulin mutation in mismatch repair-defective colorectal carcinomas

Bicknell, D., Kaklamanis, L., Hampson, R., Bodmer, W. F., & Karran, P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70795-1 · Cited by 132 · see citing works

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

Carretero, R., Romero, J. M., Ruiz‐Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008) · Immunogenetics · doi:10.1007/s00251-008-0303-5 · Cited by 128 · see citing works

HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas

López‐Nevot, M. Á., Esteban, F., FERRON, A. D., Gutiérrez, J., Mr, O., Romero, C., Huelin, C., Ruiz‐Cabello, F., & Garrido, F. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.45 · Cited by 127 · see citing works

Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

Smith, M. E., Marsh, S. G. E., Bodmer, J. G., Gelsthorpe, K., & Bodmer, W. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.14.5557 · Cited by 122 · see citing works

CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons

Guo, W., Lonardo, F., Ueda, T., Kim, T. K., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2 · Cited by 120 · see citing works

Analysis of HLA expression in human tumor tissues

Cabrera, T., López‐Nevot, M. Á., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0332-0 · Cited by 119 · see citing works

MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway

Yang, W., Li, Y., Gao, R., Xiu, Z., & Sun, T. (2019) · Oncogene · doi:10.1038/s41388-019-1045-6 · Cited by 118 · see citing works

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

Lazzari, C., Karachaliou, N., Bulotta, A., Viganò, M., Mirabile, A., Brioschi, E., Santarpía, M., Gianni, L., Rosell, R., & Gregorc, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918762094 · Cited by 117 · see citing works

Beta2‐microglobulin mutations in microsatellite unstable colorectal tumors

Kloor, M., Michel, S., Buckowitz, B., Rüschoff, J., Büttner, R., Holinski‐Feder, E., Dippold, W. G., Wagner, R., Tariverdian, M., Benner, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22691 · Cited by 116 · see citing works

Evolutionary dynamics of neoantigens in growing tumors

Lakatos, E., Williams, M. J., Schenck, R. O., Cross, W. C. H., Househam, J., Zapata, L., Werner, B., Gatenbee, C., Robertson‐Tessi, M., Barnes, C. P., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0687-1 · Cited by 116 · see citing works

Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.

PROPPER, D. J., Chao, D., Braybrooke, J. P., Bahl, P., Thavasu, P., Balkwill, F. R., Turley, H., Dobbs, N. A., Gatter, K. C., Talbot, D. C., et al. (2003) · PubMed · Cited by 115 · see citing works

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

Aptsiauri, N., Ruiz‐Cabello, F., & Garrido, F. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.006 · Cited by 115 · see citing works

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

Bernal, M., Ruiz‐Cabello, F., Concha, Á., Paschen, A., & Garrido, F. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1321-6 · Cited by 114 · see citing works

HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression

Dierssen, J. W. F., de Miranda, N. F. C. C., Ferrone, S., van Puijenbroek, M., Cornelisse, C. J., Fleuren, G. J., van Wezel, T., & Morreau, H. M. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-33 · Cited by 112 · see citing works

TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer

Ling, A., Löfgren‐Burström, A., Larsson, P. G., Li, X., Wikberg, M. L., Öberg, Å., Stenling, R., Edin, S., & Palmqvist, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356143 · Cited by 110 · see citing works

Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms

Bodmer, W. F., Browning, M. J., Krausa, P., et al. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb43994.x · Cited by 109 · see citing works

Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?

Demanet, C. J., Mulder, A., Deneys, V., et al. (2003) · Blood · doi:10.1182/blood-2003-07-2500 · Cited by 109 · see citing works

HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance

Seliger, B., Kloor, M., & Ferrone, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1171447 · Cited by 104 · see citing works

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?

Huyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 103 · see citing works

Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines

Rodríguez, T., Méndez, R., del Campo, A., Jiménez, P., Aptsiauri, N., Garrido, F., & Ruiz-Cabello, F. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-34 · Cited by 102 · see citing works

Mechanisms of loss of HLA class I expression on colorectal tumor cells

Browning, M. J., Petronzelli, F., Bicknell, D. C., Krausa, P., Rowan, A., Tonks, S., Murray, N., Bodmer, J. G., & Bodmer, W. F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02571.x · Cited by 101 · see citing works

Intrinsic β-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer

Xue, J., Yu, X., Xue, L., Ge, X., Zhao, W., & Peng, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108921 · Cited by 94 · see citing works

Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors

Seliger, B., Ruiz‐Cabello, F., & Garrido, F. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00407-7 · Cited by 93 · see citing works

Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21

Maleno, I., Cabrera, C., Cabrera, T., Paco, L., López‐Nevot, M. Á., Collado, A., Ferr�n, A., & Garrido, F. (2004) · Immunogenetics · doi:10.1007/s00251-004-0692-z · Cited by 93 · see citing works

Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms

Csiba, Á., Whitwell, H., & Moore, M. G. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.239 · Cited by 90 · see citing works

Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer

Gurjao, C., Liu, D., Hofree, M., AlDubayan, S. H., Wakiro, I., Su, M.-J., Felt, K. D., Gjini, E., Brais, L. K., Rotem, A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0683 · Cited by 90 · see citing works

HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape

Perea, F., Sánchez‐Palencia, A., Gómez‐Morales, M., Bernal, M., Concha, Á., García, M. M., Ramírez, A. R. G., Kerick, M., Martin, J. J., Garrido, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23469 · Cited by 85 · see citing works

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series

Ugurel, S., Spassova, I., Wohlfarth, J., Drusio, C., Cherouny, A., Melior, A., Sucker, A., Zimmer, L., Ritter, C., Schadendorf, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02341-9 · Cited by 85 · see citing works

Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis.

Ma, D., & Niederkorn, J. Y. (1995) · PubMed · Cited by 83 · see citing works

Strategies to counteract MHC-I defects in tumors

Lampen, M. H., & van Hall, T. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.005 · Cited by 82 · see citing works

NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8+ T lymphocytes

Rodriguez, G. M., Bobbala, D., Serrano, D., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151593 · Cited by 82 · see citing works

Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors

Maleno, I., Aptsiauri, N., Cabrera, T., Gallego, Á. O., Paschen, A., López‐Nevot, M. Á., & Garrido, F. (2010) · Immunogenetics · doi:10.1007/s00251-010-0494-4 · Cited by 81 · see citing works

Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression

Waldburger, J., Masternak, K., Mühlethaler‐Mottet, A., Villard, J., Peretti, M., LeibundGut‐Landmann, S., & Reith, W. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17813.x · Cited by 81 · see citing works

The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture

Garrido, F., Perea, F., Bernal, M., Sánchez‐Palencia, A., Aptsiauri, N., & Ruiz‐Cabello, F. (2017) · Vaccines · doi:10.3390/vaccines5010007 · Cited by 81 · see citing works

The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications

Soldevilla, B., Carretero-Puche, C., Goméz-López, G., Al‐Shahrour, F., Martínez, M. C. R., Gil-Calderón, B., Álvarez‐Vallina, L., Espinosa-Olarte, P., Gomez-Esteves, G., Rubio-Cuesta, B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.008 · Cited by 81 · see citing works

Down‐regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells

Sers, C., Kuner, R., Falk, C. S., Lund, P., Sueltmann, H., Braun, M., Buneß, A., Ruschhaupt, M., Conrad, J., Mang‐Fatehi, S., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24557 · Cited by 80 · see citing works

Oncogenic Ki-Ras Inhibits the Expression of Interferon-responsive Genes through Inhibition of STAT1 and STAT2 Expression

Klampfer, L., Huang, J., Corner, G. A., Mariadason, J. M., Arango, D., Sasazuki, T., Shirasawa, S., & Augenlicht, L. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304721200 · Cited by 79 · see citing works

Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis

Løvig, T., Andersen, S. N., Thorstensen, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600507 · Cited by 76 · see citing works

Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas

Wang, X., Waschke, B. C., Woolaver, R. A., Chen, Z., Zhang, G., Piscopio, A. D., Liu, X., & Wang, J. H. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0875 · Cited by 75 · see citing works

MHC/HLA Class I Loss in Cancer Cells

Garrido, F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-17864-2_2 · Cited by 74 · see citing works

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1515057 · Cited by 72 · see citing works

Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

Respa, A., Bukur, J., Ferrone, S., Pawelec, G., Zhao, Y., Wang, E., Marincola, F. M., & Seliger, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2114 · Cited by 71 · see citing works

Immunological landscape of consensus clusters in colorectal cancer

Karpiński, P., Rossowska, J., & Sasiadek, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22169 · Cited by 69 · see citing works

Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes

Michel, S., Linnebacher, M., Alcaniz, J., Voss, M., Wagner, R., Dippold, W. G., Becker, C., Doeberitz, M. V. K., Ferrone, S., & Kloor, M. (2009) · International Journal of Cancer · doi:10.1002/ijc.25106 · Cited by 65 · see citing works

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63 · see citing works

Loss of HLA class‐I alleles, heavy chains and β2‐microglobulin in colorectal cancer

Kaklamanis, L., Gatter, K. C., Hill, A. B., Mortensen, N., Harris, A. L., Krausa, P., McMichael, A. J., Bodmer, J. G., & Bodmer, W. F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510308 · Cited by 60 · see citing works

Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor–Immune Microenvironment in Colorectal Cancers

Yoo, S.-Y., Park, H. E., Kim, J. H., Wen, X., Jeong, S., Cho, N., Gwon, H. G., Kim, K., Lee, H. S., Jeong, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1159 · Cited by 58 · see citing works

SELECTIVE LOSS OF HLA-A,B,C LOCUS PRODUCTS IN COLORECTAL ADENOCARCINOMA

Smith, M. E., Bodmer, W. F., & Bodmer, W. F. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91682-0 · Cited by 56 · see citing works

Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness.

Gutierrez, J., López‐Nevot, M. Á., Cabrera, T., Oliva, R., Esquivias, J., Ruiz‐Cabello, F., & Garrido, F. (1987) · PubMed · Cited by 56 · see citing works

Bacillus Calmette‐Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I‐deficient tumor cells

Carretero, R., Cabrera, T., Gil-Julio, H., Sáenz-López, P., Maleno, I., Aptsiauri, N., Cozar, J. M., & Garrido, F. (2010) · International Journal of Cancer · doi:10.1002/ijc.25733 · Cited by 55 · see citing works

Targeting HLA class I expression to increase tumor immunogenicity

Campo, A. B., Carretero, J., Aptsiauri, N., & Garrido, F. (2012) · Tissue Antigens · doi:10.1111/j.1399-0039.2011.01831.x · Cited by 53 · see citing works

Locus-Specific Analysis of Human Leukocyte Antigen Class I Expression in Melanoma Cell Lines

Marincola, F. M., Shamamian, P. E., Simonis, T. B., Abati, A. D., Hackett, J., Dea, T. O., Fetsch, P. A., Yannelli, J. R., Restifo, N. P., Mulé, J. J., et al. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199407000-00002 · Cited by 51 · see citing works

Biological Implications of HLA‐DR Expression in Tumours

Cabrera, T., Ruiz‐Cabello, F., & Garrido, F. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03584.x · Cited by 50 · see citing works

Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.

Park, J., Thomas, S., & Munster, P. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 49 · see citing works

Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer

Warabi, M., Kitagawa, M., & Hirokawa, K. (2000) · Pathology - Research and Practice · doi:10.1016/s0344-0338(00)80080-1 · Cited by 48 · see citing works

Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence

Möller, P., Koretz, K., Schlag, P., et al. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470727 · Cited by 44 · see citing works

Generation of CD8 + T cells specific for transporter associated with antigen processing deficient cells

Wolpert, E. Z., Petersson, M., Chambers, B. J., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11496 · Cited by 42 · see citing works

Revisiting immune escape in colorectal cancer in the era of immunotherapy

Ijsselsteijn, M. E., Petitprez, F., Lacroix, L., Ruano, D., van der Breggen, R., Julié, C., Morreau, H., Sautès‐Fridman, C., Fridman, W. H., & de Miranda, N. F. C. C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0421-x · Cited by 42 · see citing works

HLA‐DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers

Walsh, M. D., Dent, O. F., Young, J. P., Wright, C. M., Barker, M., Leggett, B., Bokey, L., Chapuis, P. H., Jass, J. R., & Macdonald, G. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24484 · Cited by 41 · see citing works

Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer

Surmann, E.-M., Voigt, A. Y., Michel, S., Bauer, K. H., Reuschenbach, M., Ferrone, S., Doeberitz, M. V. K., & Kloor, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1638-4 · Cited by 40 · see citing works

Efficient Recovery of HLA Class I Expression in Human Tumor Cells After Beta2‐Microglobulin Gene Transfer Using Adenoviral Vector: Implications for Cancer Immunotherapy

Campo, A. B., Aptsiauri, N., Méndez, R., Zinchenko, S. P., Vales, Á., Paschen, A., Ward, S., Ruiz‐Cabello, F., González‐Aseguinolaza, G., & Garrido, F. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02276.x · Cited by 40 · see citing works

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

Vlková, V., Štěpánek, I., Hrušková, V., Šenigl, F., Mayerová, V., Šrámek, M., Šímová, J., Bieblová, J., Indrová, M., Hejhal, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2222 · Cited by 39 · see citing works

Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases

de Miranda, N. F. C. C., Goudkade, D., Jordanova, E. S., Tops, C. M. J., Hes, F. J., Vasen, H. F. A., van Wezel, T., & Morreau, H. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1997 · Cited by 39 · see citing works

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Ledys, F., Klopfenstein, Q., Truntzer, C., Arnould, L., Vincent, J., Bengrine-Lefèvre, L., Remark, R., Boidot, R., Ladoire, S., Ghiringhelli, F., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0438-3 · Cited by 39 · see citing works

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression

Durrant, L., Ballantyne, K., Armitage, N. C. M., et al. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.218 · Cited by 37 · see citing works

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab

Garrido, G., Rabasa, A., Garrido, C., Chao, L., Garrido, F., Garcia-Lora, A. M., & Sánchez-Ramírez, B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00595 · Cited by 37 · see citing works

DIFFERENT PATTERNS OF HLA‐DR ANTIGEN EXPRESSION IN NORMAL EPITHELIUM, HYPERPLASTIC AND NEOPLASTIC MALIGNANT LESIONS OF THE BREAST

Concha, Á., Ruiz‐Cabello, F., Cabrera, T., et al. (1995) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.1995.tb00246.x · Cited by 36 · see citing works

Loss of polymorphic A and B locus HLA antigens in colon carcinoma

Rees, R. C., Buckle, A.-M., Gelsthorpe, K., et al. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.85 · Cited by 36 · see citing works

Targetless T cells in cancer immunotherapy

Straten, P. T., & Garrido, F. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0127-z · Cited by 36 · see citing works

Characterising the prognostic potential of HLA-DR during colorectal cancer development

Dunne, M. R., Phelan, J. J., Michielsen, A. J., Maguire, A. A., Dunne, C., Martin, P., Noonan, S. A., Tosetto, M., Geraghty, R., Fennelly, D. W., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02571-2 · Cited by 36 · see citing works

Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon.

Tsioulias, G. J., Triadafilopoulos, G., Goldin, E., et al. (1993) · PubMed · Cited by 35 · see citing works

Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition

Campo, A. B., Carretero, J., Muñoz, J. A., Zinchenko, S. P., Ruiz‐Cabello, F., González‐Aseguinolaza, G., Garrido, F., & Aptsiauri, N. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.32 · Cited by 35 · see citing works

Immunotherapy eradicates metastases with reversible defects in MHC class I expression

Garrido, C., Romero, I., Berruguilla, E., Cancela, B., Algarra, I., Collado, A., Garcia-Lora, A. M., & Garrido, F. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1027-1 · Cited by 32 · see citing works

MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy

Romero, I., Garrido, C., Algarra, I., Chamorro, V., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00102 · Cited by 32 · see citing works

MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells

Wang, X., Waschke, B. C., Woolaver, R. A., Chen, S. M. Y., Chen, Z., & Wang, J. H. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0463-2 · Cited by 30 · see citing works

Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape

Bernal, M., García-Alcalde, F., Concha, Á., Cano, C., Blanco, A. J., Garrido, F., & Ruiz‐Cabello, F. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1147-7 · Cited by 27 · see citing works

Molecular analysis of MHC-class-I alterations in human tumor cell lines

Ruiz‐Cabello, F., Perez‐Ayala, M., Gomez, O., et al. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470723 · Cited by 27 · see citing works

Interconnectivity between molecular subtypes and tumor stage in colorectal cancer

Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07316-z · Cited by 27 · see citing works

Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors

Cabrera, C. M., López‐Nevot, M. Á., Jiménez, P., & Garrido, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20526 · Cited by 25 · see citing works

Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas

On behalf of investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort, Clendenning, M., Huang, A., Jayasekara, H., Lorans, M., Preston, S., O’Callaghan, N., Pope, B. J., Macrae, F., Winship, I., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-0013-y · Cited by 25 · see citing works

MHC Class-I Loss and Cancer Immune Escape

Garrido, F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-17864-2 · Cited by 20 · see citing works

Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine

Pulido, M., Chamorro, V., Romero, I., Algarra, I., Montalvo, A. S., Collado, A., Garrido, F., & Garcia-Lora, A. M. (2020) · Cancers · doi:10.3390/cancers12061563 · Cited by 19 · see citing works

Expression of histocompatibility antigens and characterization of the lymphocyte infiltrate in hyperplastic polyps of the large bowel

Bédossa, P., Poynard, T., Bacci, J., et al. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90233-u · Cited by 12 · see citing works

EXPRESSION OF MHC CLASS II PRODUCTS ON HUMAN COLORECTAL CANCER AN IMMUNOHISTOLOGICAL AND FLOW CYTOMETRIC STUDY

Moore, M. G., Ghosh, A. K., Johnston, D., et al. (1986) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.1986.tb01102.x · Cited by 11 · see citing works

HLA antigens on colorectal adenoma and cancer cells.

Horie, Y., Chiba, M., Iizuka, M., et al. (1990) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.160.311 · Cited by 5 · see citing works

Introduction

Garrido, F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-17864-2_1 · Cited by 4 · see citing works

Current and emerging concepts for systemic treatment of metastatic colorectal cancer

Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · see citing works

HLA‐G Polymorphisms: Ethnic Differences and Implications for Potential Molecule Function

van der Ven, K., Skrablin, S., Ober, C., et al. (1998) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1998.tb00406.x · Cited by 24 · see citing works

The Advance in the Association between Recurrent Spontaneous Abortion and Human LeukocyteAntigen-G

Da-chun, H. (2009) · Medical Recapitulate

HLA-G as a Tolerogenic Molecule in Transplantation and Pregnancy

Rebmann, V., Nardi, F. D. S., Wagner, B., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/297073 · Cited by 122 · see citing works

The involvement of HLA-E and -F in pregnancy

Ishitani, A., Sageshima, N., & Hatake, K. (2006) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2005.10.004 · Cited by 101 · see citing works

Is HLA ‐E a possible genetic marker relevant for natural conception?

Gelmini, G. F., Costa, C. H., Nardi, F. D. S., et al. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12587 · Cited by 7 · see citing works